| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells). Rubipodanone A is reported to show an activating effect on NF-kappaB at concentrations of 20 uM and 40 uM, in contrast to many other natural products that inhibit this pathway.
|
|---|---|
| ln Vitro |
Rubipodanone A demonstrates cytotoxicity (IC50=16.77-31.89 μM) against A549, BEL-7402, HeLa, HepG2, SGC-7901, and U251 cells[1].
Rubipodanone A demonstrates broad-spectrum cytotoxicity against human cancer cell lines A549 (lung), BEL-7402 (liver), HeLa (cervical), HepG2 (liver), SGC-7901 (gastric), and U251 (glioma), with IC50 values ranging from 16.77 to 31.89 uM. Additionally, it shows an obvious activating effect on NF-kappaB at 20 uM and 40 uM, which may contribute to its cytotoxic activity through induction of NF-kappaB-mediated pro-apoptotic signals. |
| ln Vivo |
No direct in vivo data. As a natural naphthohydroquinone dimer with potent in vitro cytotoxicity, Rubipodanone A may have potential anti-tumor activity in vivo, but comprehensive animal studies are lacking. Further research is required to determine its bioavailability, pharmacokinetics, and in vivo efficacy in xenograft models.
|
| Enzyme Assay |
(1) NF-kappaB activation assay: Transfect HEK293 cells with NF-kappaB luciferase reporter plasmid (e.g., pNF-kappaB-Luc) and control Renilla. (2) Treat cells with Rubipodanone A (20-40 uM) for 6-24 h. (3) Lyse cells, add Dual-Luciferase reagents, measure firefly and Renilla luminescence. (4) Alternatively, use EMSA with nuclear extracts and 32P-labeled NF-kappaB probe, or measure p65 nuclear translocation by immunofluorescence.
|
| Cell Assay |
(1) Seed A549, HepG2, or HeLa cells (5,000-10,000/well) in 96-well plates overnight. (2) Treat with Rubipodanone A (0-100 uM, 48-72 h). (3) Add CCK-8 or MTT reagent, incubate 2-4 h, measure OD450 or OD570. (4) Calculate IC50 using nonlinear regression (GraphPad Prism). (5) For apoptosis: stain with Annexin V-FITC/PI after 48 h, analyze by flow cytometry. (6) For NF-kappaB activation: treat cells at 20-40 uM for 6-12 h, then perform p65 immunofluorescence or Western blot of nuclear fractions.
|
| Animal Protocol |
In vivo experimental design for Rubipodanone A has not been reported. However, a standard protocol for related naphthohydroquinone dimers would involve: (1) 6-8 week old female BALB/c nude mice bearing A549 or HepG2 xenografts (100-200 mm3). (2) Administer Rubipodanone A intraperitoneally (10-50 mg/kg daily or every other day) or by oral gavage. (3) Formulation: dissolve in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline. (4) Monitor tumor volume and body weight for 14-21 days. (5) Endpoint: tumor weight, IHC for Ki-67 and cleaved caspase-3.
|
| ADME/Pharmacokinetics |
No PK data available for Rubipodanone A. Based on its molecular weight (442.46) and LogP (~4.7), it is expected to have moderate lipophilicity and potential for good membrane permeability. Standard formulation for in vivo administration of naphthohydroquinone dimers: dissolve in DMSO (stock), then dilute in 10% DMSO, 40% PEG300, 5% Tween-80, 45% saline for IP/IV/IM/SC injection, or in 5% DMSO, 5% Tween-80, 90% saline for low-dose IV administration.
|
| Toxicity/Toxicokinetics |
In vitro toxicity: CCK-8 assay on non-cancerous cell lines (e.g., HEK293, MCF-10A). No reported in vivo toxicity. General toxicity for similar naphthohydroquinones includes potential glutathione depletion and oxidative stress at high concentrations (IC50 ~ 30-100 uM in normal cells). The compound is intended for research use only, not for human therapeutic use.
|
| References | |
| Additional Infomation |
Rubipodanone A is a natural naphthohydroquinone dimer that shows promising anti-cancer activity across multiple cell lines. Importantly, unlike many other NF-kappaB modulators that are inhibitors, Rubipodanone A is an NF-kappaB activator, suggesting that its cytotoxic mechanism may involve NF-kappaB-mediated induction of pro-inflammatory or pro-apoptotic gene expression. It is isolated from Rubia yunnanensis, a plant used in traditional Chinese medicine. This product is not approved by any regulatory authority for human use and is strictly for laboratory research purposes, including chemical biology studies, natural product chemistry, and anti-cancer drug discovery.
|
| Molecular Formula |
C27H22O6
|
|---|---|
| Molecular Weight |
442.46
|
| Exact Mass |
442.141
|
| CAS # |
2170211-22-8
|
| PubChem CID |
134715233
|
| Appearance |
White to yellow solid powder
|
| Boiling Point |
647.0±55.0 °C(Predicted)
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
979
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C1C2C=CC=CC=2C(=C(C(=O)OC)C1(C1=CC(C2C=CC=CC=2C1=O)=O)C/C=C(\C)/C)O
|
| InChi Key |
CDHHYGYUIPPDJB-HHHXNRCGSA-N
|
| InChi Code |
InChI=1S/C27H22O6/c1-15(2)12-13-27(20-14-21(28)16-8-4-5-9-17(16)23(20)29)22(26(32)33-3)24(30)18-10-6-7-11-19(18)25(27)31/h4-12,14,30H,13H2,1-3H3/t27-/m1/s1
|
| Chemical Name |
methyl (3R)-3-(1,4-dioxonaphthalen-2-yl)-1-hydroxy-3-(3-methylbut-2-enyl)-4-oxonaphthalene-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2601 mL | 11.3005 mL | 22.6009 mL | |
| 5 mM | 0.4520 mL | 2.2601 mL | 4.5202 mL | |
| 10 mM | 0.2260 mL | 1.1300 mL | 2.2601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
